Sign In
Buy ABBV
$227.23
+2.30 (+1.02%)
At Close: Jun 05, 2026
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
09:45pm, Monday, 19'th Sep 2022 Zacks Investment Research
AbbVie (ABBV) closed the most recent trading day at $142.66, moving -0.97% from the previous trading session.
Top Analyst Reports for Apple, Amazon.com & AbbVie
08:17pm, Monday, 19'th Sep 2022 Zacks Investment Research
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Amazon.com, Inc. (AMZN) and AbbVie Inc. (ABBV).
3 Passive-Income Stock Secrets You'll Wish You Knew Earlier
02:37pm, Monday, 19'th Sep 2022 The Motley Fool
You'll have more success with dividend investing with the right approach.
AbbVie: Valuation Attractive Due To Humira Headwinds
11:32am, Monday, 19'th Sep 2022
AbbVie is a global biopharmaceutical company with a vast portfolio of drugs and therapies. Its blockbuster drug, Humira, is set to lose exclusivity in 2023.
The Zacks Analyst Blog Highlights AbbVie, Novartis, Merck and AstraZeneca
10:43am, Monday, 19'th Sep 2022 Zacks Investment Research
AbbVie, Novartis, Merck and AstraZeneca are included in this Analyst Blog.
4 Strategies to Try if You Need Extra Cash From Your Investments
09:51am, Monday, 19'th Sep 2022 The Motley Fool
Cash is still king in many different contexts.
Calif. Pharmaceutical Companies AbbVie And Bristol Myers Lay Off 360—Here Are The Major U.S. Layoffs This Summer
01:13pm, Saturday, 17'th Sep 2022
Forbes is tracking the biggest layoffs in the U.S. this summer as companies react to fears of a looming recession.
4 Large Drug Stocks to Watch as Fundamentals Stay Strong
01:58pm, Friday, 16'th Sep 2022 Zacks Investment Research
Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, AbbVie (ABBV), Novartis (NVS), Merck (MRK) and AstraZeneca (AZN) are wor
Consumer group says drugmakers abuse U.S. patent system to keep prices high
08:41pm, Thursday, 15'th Sep 2022
Makers of the top selling drugs in the United States are costing patients billions of dollars and worsening a drug pricing crisis by abusing the U.S. patent system to stifle competition and inflate pr
Outlook For AbbVie Continues To Look Favorable
06:42pm, Thursday, 15'th Sep 2022
AbbVie has delivered strong earnings over recent quarters. The total return on ABBV over the past year is 36.6%.
7 Top-Rated Biotech Stocks to Buy for Q4
03:00pm, Thursday, 15'th Sep 2022
A new White House program will likely boost the entire biotech industry. And it makes these seven names some outstanding biotech stocks to buy for the fourth quarter.
AbbVie to Present Data from Growing Neuroscience and Movement Disorders Portfolio at 2022 MDS International Congress
02:00am, Thursday, 15'th Sep 2022
--Results will be presented from the Phase 3 M15-736 trial, a randomized, double-blind, double-dummy, active-controlled study, evaluating the continuous subcutaneous infusion of ABBV-951 (foslevodopa/
AbbVie Inc.'s (ABBV) Management Presents at Morgan Stanley 20th Annual Global Healthcare Conference (Transcript)
12:26pm, Wednesday, 14'th Sep 2022
AbbVie Inc. (NYSE:ABBV ) Morgan Stanley 20th Annual Global Healthcare Conference September 13, 2022 10:35 AM ET Company Participants Rob Michael - Vice Chairman and President Jeff Stewart - Executive
Bristol-Myers versus AbbVie stock: Expert picks a side
02:22pm, Tuesday, 13'th Sep 2022 Invezz
AbbVie Inc (NYSE: ABBV) is a better long-term investment than peer Bristol-Myers Squibb Co (NYSE: BMY) even though the latter just secured FDA approval for its Psoriasis pill, says Mohit Bansal. He’
3 No-Brainer Stocks to Buy in a Correction
02:15pm, Tuesday, 13'th Sep 2022 The Motley Fool
The trick is to know where to look.
